Stock Updates

A look at a High Market Cap Stock: Alexion Pharmaceuticals, Inc., ALXN

Alexion Pharmaceuticals, Inc., ALXN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Alexion Pharmaceuticals, Inc., ALXN  has a market cap of 26518.69. Since its IPO date on the 2/28/1996, Alexion Pharmaceuticals, Inc., ALXN performance year to date is -37.96%. Today Alexion Pharmaceuticals, Inc., ALXN has gained -1.06%, with a current price of 118.34.

Ownership of the company is 0.50% for insider ownership while institutional ownership is 93.90%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 0.70%, with return on investment at 1.60%.

In terms of debt levels and profit levels, Alexion Pharmaceuticals, Inc., ALXN is seeing a long-term debt/equity of 0.39. While Total debt/equity is 0.4. With a profit margin of 3.20%, this is combined with a gross margin of 91.80%, and operating margin of 21.70%. Alexion Pharmaceuticals, Inc. ability to meet debt levels, with a current ratio of 3.6, while the quick ratio is 3.1.

For the last year Alexion Pharmaceuticals, Inc., ALXN has seen a EPS growth of -79.50%. A performance for the year of -26.53%. The 52-week high is -38.83%, and the 52-week low is 7.04%. The average volume for Alexion Pharmaceuticals, Inc., ALXN is 957975.

With a target price of 167.11, can Alexion Pharmaceuticals, Inc., ALXN reach this target? Looking at the value indicators of Alexion Pharmaceuticals, Inc., ALXN. Alexion Pharmaceuticals, Inc. has a P/E of 299.59 and a forward P/E of 20.26. Perhaps the more useful indicator than P/E, is PEG which has a value of 16.39. Alexion Pharmaceuticals, Inc. also has a P/S and a P/B of 9.4 and 3.23 respectively. For P/cash, Alexion Pharmaceuticals, Inc. has a value of 22.47, while it is 49.23 for P/free cash flow.

At the current price of 118.34, Alexion Pharmaceuticals, Inc. has a dividend yield of *TBA. We see a return on equity of 1.10%.

Looking more long-term Alexion Pharmaceuticals, Inc., is projected to get an EPS growth for the next five years of 18.28%. In the short-term an EPS growth of 25.04% in the next year is forecasted. This is after a EPS growth of -79.50% for this year and for the last five years a 5.10% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Tony Dabbs

Leave a Comment